单腔静脉导管实施闭式引流联合凝血酶胸腔注入治疗结核性气胸

摘要

Objective:To investigate single cavity vein catheter closed drainage combined thrombin injection in the treatment of tuberculous pneumothorax.Method:From March 2015 to March 2016,100 cases of tuberculosis pneumothorax in our hospital were selected as the research objects,they were divided into the control group and treatment group,each group had 50 cases.The control group were treated with routine treatment,the treatment group were treated with single cavity vein catheter closed drainage combined thrombin injection,the clinical efficacy,pulmonary rehabilitation time,hospitalization expenses and time,recovery and adverse reaction of two groups were compared.Result:After treatment,the cure rate of the treatment group was 84.0%,higher than 98.0% of the control group,the difference was statistically significant(P<0.05).The hospitalization expenses, hospitalization time and pulmonary rehabilitation time in the treatment group were all lower than those in control group,the differences were statistically significant(P<0.05).The health rate of the treatment group was 80.0%, better than 60.0% of the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the treatment group was 8.0%,lower than 26.0% of the control group,the difference was statistically significant(P<0.05).Conclusion:Single cavity vein catheter closed drainage combined thrombin injection is a kind of novel,superior and safe pneumothorax therapy,have high treatment efficiency,good safety, shorten period of treatment and reduce recurrence and reduce cost of treatment,is worth of clinical promotion.%目的：探讨单腔静脉导管实施闭式引流联合凝血酶胸腔注入治疗结核性气胸。方法：选取2015年3月-2016年3月本院收治的100例结核性气胸患者作为研究对象，随机分为对照组和治疗组，每组50例。对照组采用常规治疗，治疗组采用单腔静脉导管实施闭式引流联合凝血酶胸腔注入，比较两组患者临床疗效、肺复张时间、住院费用与时间、恢复情况及不良反应发生情况。结果：治疗后，治疗组治愈率为98.0%，高于对照组的84.0%，比较差异有统计学意义（P<0.05）；治疗组住院时间、住院费用及肺复张时间均低于对照组，比较差异均有统计学意义（P<0.05）；治疗组健康率为80.0%，明显优于对照组的60.0%，比较差异有统计学意义（P<0.05）；治疗组不良反应发生率为8.0%，低于对照组的26.0%，比较差异有统计学意义（P<0.05）。结论：单腔静脉导管实施闭式引流联合凝血酶胸腔注入凝血酶方法治疗结核性气胸是一种新颖、优越、安全的气胸治疗方法，具有治疗效率高、安全性好、缩短疗程、减少复发与治疗费用等优点，值得临床推广。